Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice
https://doi.org/10.21518/2079-701X-2018-21-96-104
Abstract
Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia. The prevalence and high mortality of this disease lead to a significant socio-economic burden. A pharmacoeconomic comparison of two alternative drug technologies in the studied groups grants the reasonable opportunity to transfer patients to the domestic analogues, confirming that efficiency unit costs for using Tiotropium-native and Ipraterol-native are lower than the same costs for using the foreign drugs Spiriva and Berodual.
About the Authors
Р. A. Balunov
REMEDIUM GROUP LLC
Russian Federation
Russian Federation
Balunov Pavel Andreevich – Science Editor
Bldg. 10, House 71, Bakuninskaya Ul., Moscow, 105082
A. N. Khitrov
Federal State Autonomous Educational Institution of Higher Education «Sechenov First Moscow State Medical University» of Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Khitrov Alexandr Nikolaevich – Dr. of Sci.(Med.), Associate Professor
Bldg. 2, House 8, Trubetskaya Str., Moscow, 119991
References
1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2019 Report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf.
2. http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/.
3. Gino Scalone. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL – The prospective cohort, observational study. Pulmonary Pharmacology & Therapeutics. 2018; 53: 68-77/
4. Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397-412.
5. World Health Organization. Projections of mortality and causes of death, 2015 and 2030. http://www.who.int/healthinfo/global_burden_disease/projections/en/ (accessed 14 October 2018).
6. Adeloye D., Chua S., Lee C., Basquill C., Papana A., Theodoratou E., Nair H., Gasevic D., Sridhar D., Campbell H. et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015; 5.
7. Chronic obstructive pulmonary disease: a guide for practitioners. S.I. Ovcharenko, I.V. Leshchenko [et al.]. Under the editorship of A.G. Chuchalin. M.: GEOTAR-Media, 2016. 192 p. (“A medical specialist’s library” series). ISBN 978-5-9704-3578-6. (In Russ).
8. Smoking and chronic obstructive pulmonary disease. Kirov: EV, CMP KOGBUZ “MIAC”, 2017. http://sovetskcrb.medkirov.ru/. (In Russ).
9. COPD http://hobl-online.ru/.
10. Miller J.D., Foster T., Boulanger L. et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005; 2: 311-318.
11. Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease (revision 2014). Trans. from English under the editorship of A.S. Belevsky. M.: Russian Respiratory Society, 2014. 92 p., Ill. (In Russ).
12. Celli B.R., MacNee W., Agusti A. et al. European Respiratory Journal. 2004; 23 (6): 932-946.
13. Nedogoda S.V., Tsoma V.V., Ledyaeva A.A., Khripaeva V.Yu. Modern possibilities for COPD management in Russia: from clinical guidelines to real practice. Effektivnaya Farmakoterapia. 2017; 14: 24-32. (In Russ).
14. Wiesel A.A., Ermolova S.O., Berdnikova N.G., et al. Bronchodilator therapy in real clinical practice: a comparison of the original foreign and domestic generics. RMJ. Pulmonologiya. 2017; 25, 18: 1275–1280. (In Russ).
15. The state register of maximal selling prices. http://grls.rosminzdrav.ru/PriceLims.aspx. (In Russ).
16. Makarova M.A. Smoking and chronic obstructive pulmonary disease. Astma i Allergiya. 2016; 4: 19-20. (In Russ).
Review
For citations:
Balunov РA, Khitrov AN. Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice. Meditsinskiy sovet = Medical Council. 2018;(21):96-104. (In Russ.) https://doi.org/10.21518/2079-701X-2018-21-96-104
Views:
2562
Email this article 